California State Teachers Retirement System Takes Position in Cencora, Inc. (NYSE:COR)

California State Teachers Retirement System bought a new stake in Cencora, Inc. (NYSE:COR) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 266,658 shares of the company’s stock, valued at approximately $64,795,000. California State Teachers Retirement System owned 0.13% of Cencora at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in COR. Vanguard Group Inc. acquired a new position in shares of Cencora in the 4th quarter valued at about $4,212,508,000. Price T Rowe Associates Inc. MD acquired a new position in Cencora in the first quarter worth approximately $2,183,619,000. JPMorgan Chase & Co. acquired a new position in Cencora in the first quarter worth approximately $1,199,695,000. Capital Research Global Investors acquired a new position in Cencora in the first quarter worth approximately $650,424,000. Finally, Bessemer Group Inc. acquired a new position in Cencora in the first quarter worth approximately $556,245,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling

In other news, Director Dermot Mark Durcan acquired 500 shares of the stock in a transaction that occurred on Friday, May 24th. The stock was purchased at an average cost of $218.58 per share, for a total transaction of $109,290.00. Following the completion of the transaction, the director now directly owns 21,876 shares in the company, valued at $4,781,656.08. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Dermot Mark Durcan bought 500 shares of Cencora stock in a transaction on Friday, May 24th. The shares were purchased at an average price of $218.58 per share, for a total transaction of $109,290.00. Following the completion of the acquisition, the director now owns 21,876 shares in the company, valued at $4,781,656.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Gina Clark sold 1,874 shares of the firm’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $223.86, for a total value of $419,513.64. Following the transaction, the executive vice president now owns 13,284 shares in the company, valued at approximately $2,973,756.24. The disclosure for this sale can be found here. Insiders sold a total of 1,899,112 shares of company stock worth $408,654,376 over the last three months. 15.80% of the stock is currently owned by company insiders.

Cencora Trading Up 0.8 %

COR stock traded up $1.98 during midday trading on Thursday, reaching $239.86. The stock had a trading volume of 37,459 shares, compared to its average volume of 1,365,057. The business has a fifty day simple moving average of $227.78 and a two-hundred day simple moving average of $230.89. The company has a quick ratio of 0.53, a current ratio of 0.89 and a debt-to-equity ratio of 3.41. The firm has a market cap of $47.84 billion, a price-to-earnings ratio of 26.02, a PEG ratio of 1.60 and a beta of 0.45. Cencora, Inc. has a twelve month low of $171.65 and a twelve month high of $246.75.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. The firm had revenue of $74.20 billion during the quarter, compared to analyst estimates of $73.32 billion. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The company’s revenue was up 10.8% on a year-over-year basis. During the same period last year, the company earned $2.92 earnings per share. As a group, research analysts expect that Cencora, Inc. will post 13.46 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 26th. Investors of record on Friday, August 9th will be given a $0.51 dividend. The ex-dividend date of this dividend is Friday, August 9th. This represents a $2.04 dividend on an annualized basis and a yield of 0.85%. Cencora’s payout ratio is 22.32%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Robert W. Baird increased their price objective on Cencora from $285.00 to $287.00 and gave the stock an “outperform” rating in a report on Thursday. SVB Leerink restated an “outperform” rating and issued a $275.00 price objective on shares of Cencora in a report on Thursday, June 27th. Citigroup increased their price objective on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Finally, StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $239.00.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.